Purchase by Enrique Poradosu of 500 shares of Nuvectis Pharma
| NVCT Stock | USD 5.04 0.24 4.55% |
Slightly above 62% of Nuvectis Pharma's investor base is looking to short. The analysis of overall sentiment of trading Nuvectis Pharma stock suggests that many investors are alarmed at this time. Nuvectis Pharma's investing sentiment can be driven by a variety of factors including economic data, Nuvectis Pharma's earnings reports, geopolitical events, and overall market trends.
Nuvectis |
Filed transaction by Nuvectis Pharma Inc officer. General open market or private purchase of non-derivative or derivative security
Read at macroaxis.com
Nuvectis Pharma Fundamental Analysis
We analyze Nuvectis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nuvectis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nuvectis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Nuvectis Pharma is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Nuvectis Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Nuvectis Pharma stock to make a market-neutral strategy. Peer analysis of Nuvectis Pharma could also be used in its relative valuation, which is a method of valuing Nuvectis Pharma by comparing valuation metrics with similar companies.
Peers
Nuvectis Pharma Related Equities
| GLUE | Monte Rosa | 13.72 | ||||
| LYRA | Lyra Therapeutics | 10.53 | ||||
| CCCC | C4 Therapeutics | 8.59 | ||||
| CMPX | Compass Therapeutics | 4.49 | ||||
| OLMA | Olema Pharmaceuticals | 4.12 | ||||
| CGEM | Cullinan Oncology | 2.75 | ||||
| EWTX | Edgewise Therapeutics | 2.48 | ||||
| IKNA | Ikena Oncology | 2.37 | ||||
| CNTA | Centessa Pharmaceuticals | 1.76 | ||||
| HOWL | Werewolf Therapeutics | 1.52 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
| REPL | Replimune | 0.21 | ||||
| AVTE | Aerovate Therapeutics | 0.38 | ||||
| CELC | Celcuity LLC | 0.39 | ||||
| KRON | Kronos Bio | 1.04 | ||||
| IVA | Inventiva | 1.12 | ||||
| GOSS | Gossamer Bio | 1.41 | ||||
| OBIO | Orchestra BioMed | 2.60 | ||||
| NAMS | NewAmsterdam Pharma | 4.57 | ||||
| LRMR | Larimar Therapeutics | 4.67 | ||||
| ELYM | Eliem Therapeutics | 5.88 |
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.